COHERUS BIOSCIENCES, INC.

(CHRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Coherus BioSciences : Barclays Adjusts Price Target on Coherus BioSciences to $24 From $28, Maintains Overweight Rating

05/17/2021 | 06:48am EDT


© MT Newswires 2021
All news about COHERUS BIOSCIENCES, INC.
05/24TRANSCRIPT : Coherus BioSciences, Inc. Presents at UBS Global Healthcare Conference, May-2..
CI
05/20COHERUS BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/20Coherus Biosciences, Inc. Ratifies Selection of Ernst & Young LLP as the Independent Re..
CI
05/20Mizuho Securities Cuts Price Target on Coherus BioSciences to $25 From $30, Reiterates ..
MT
05/13COHERUS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/12TRANSCRIPT : Coherus BioSciences, Inc. Presents at Bank of America 2022 Healthcare Confere..
CI
05/11Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors
GL
05/11Coherus BioSciences Appoints Jill O’Donnell-Tormey to Its Board of Directors, Nomi..
CI
05/11Blow to Roche's cancer immunotherapy prospects as 2nd trial fails
RE
05/10COHERUS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Analyst Recommendations on COHERUS BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 257 M - -
Net income 2022 -278 M - -
Net Debt 2022 239 M - -
P/E ratio 2022 -2,25x
Yield 2022 -
Capitalization 594 M 594 M -
EV / Sales 2022 3,24x
EV / Sales 2023 2,02x
Nbr of Employees 346
Free-Float 87,2%
Chart COHERUS BIOSCIENCES, INC.
Duration : Period :
Coherus BioSciences, Inc. Technical Analysis Chart | CHRS | US19249H1032 | MarketScreener
Technical analysis trends COHERUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 7,67 $
Average target price 20,43 $
Spread / Average Target 166%
EPS Revisions
Managers and Directors
Denny M. Lanfear Chairman, President & Chief Executive Officer
McDavid Stilwell Chief Financial Officer
Vladimir Vexler Chief Scientific Officer
Richard L. Hameister Chief Technical Officer
Rosh Dias Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
COHERUS BIOSCIENCES, INC.-51.94%594
GILEAD SCIENCES, INC.-11.38%80 715
REGENERON PHARMACEUTICALS, INC.8.63%73 916
VERTEX PHARMACEUTICALS22.26%68 665
WUXI APPTEC CO., LTD.-22.20%40 017
BIONTECH SE-40.07%37 546